BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 38505842)

  • 1. Discovery and Characterization of Active CBP/EP300 Degraders Targeting the HAT Domain.
    Cheng-Sánchez I; Gosselé KA; Palaferri L; Kirillova MS; Nevado C
    ACS Med Chem Lett; 2024 Mar; 15(3):355-361. PubMed ID: 38505842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinetic Detection of E3:PROTAC:Target Ternary Complexes Using NanoBRET Technology in Live Cells.
    Mahan SD; Riching KM; Urh M; Daniels DL
    Methods Mol Biol; 2021; 2365():151-171. PubMed ID: 34432243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploration of bromodomain ligand-linker conjugation sites for efficient CBP/p300 heterobifunctional degrader activity.
    Kumar Tiwari P; Reddy Doda S; Vannam R; Hudlikar M; Harrison DA; Ojeda S; Rai S; Koglin AS; Nguyen Gilbert A; Ott CJ
    Bioorg Med Chem Lett; 2024 Apr; 102():129676. PubMed ID: 38408512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of decoy oligonucleotide-warheaded chimeric molecules targeting STAT3.
    Shih PC; Naganuma M; Tsuji G; Demizu Y; Naito M
    Bioorg Med Chem; 2023 Nov; 95():117507. PubMed ID: 37922656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advancements in the discovery of cereblon-based protease-targeted chimeras with potential for therapeutic intervention.
    Singh H; Agrawal DK
    Future Med Chem; 2022 Oct; 14(19):1403-1416. PubMed ID: 36047364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling the CRL4A ligase complex to predict target protein ubiquitination induced by cereblon-recruiting PROTACs.
    Bai N; Riching KM; Makaju A; Wu H; Acker TM; Ou SC; Zhang Y; Shen X; Bulloch DN; Rui H; Gibson BW; Daniels DL; Urh M; Rock BM; Humphreys SC
    J Biol Chem; 2022 Apr; 298(4):101653. PubMed ID: 35101445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization of PROTAC Ternary Complex Using DNA Encoded Library Approach.
    Chen Q; Liu C; Wang W; Meng X; Cheng X; Li X; Cai L; Luo L; He X; Qu H; Luo J; Wei H; Gao S; Liu G; Wan J; Israel DI; Li J; Dou D
    ACS Chem Biol; 2023 Jan; 18(1):25-33. PubMed ID: 36606710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective degradation of EGFR
    Qu X; Liu H; Song X; Sun N; Zhong H; Qiu X; Yang X; Jiang B
    Eur J Med Chem; 2021 Jun; 218():113328. PubMed ID: 33773286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in targeted protein degraders as potential therapeutic agents.
    Yang N; Kong B; Zhu Z; Huang F; Zhang L; Lu T; Chen Y; Zhang Y; Jiang Y
    Mol Divers; 2024 Feb; 28(1):309-333. PubMed ID: 36790583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Modular Chemistry Platform for the Development of a Cereblon E3 Ligase-Based Partial PROTAC Library.
    Almodóvar-Rivera CM; Zhang Z; Li J; Xie H; Zhao Y; Guo L; Mannhardt MG; Tang W
    Chembiochem; 2023 Oct; 24(20):e202300482. PubMed ID: 37418320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a covalent cereblon-based PROTAC employing a fluorosulfate warhead.
    Nowak RP; Ragosta L; Huerta F; Liu H; Ficarro SB; Cruite JT; Metivier RJ; Donovan KA; Marto JA; Fischer ES; Zerfas BL; Jones LH
    RSC Chem Biol; 2023 Nov; 4(11):906-912. PubMed ID: 37920397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones.
    Ishida T; Ciulli A
    SLAS Discov; 2021 Apr; 26(4):484-502. PubMed ID: 33143537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expansion of targeted degradation by Gilteritinib-Warheaded PROTACs to ALK fusion proteins.
    Yokoo H; Tsuji G; Inoue T; Naito M; Demizu Y; Ohoka N
    Bioorg Chem; 2024 Apr; 145():107204. PubMed ID: 38377822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Cell-Based Target Engagement Assay for the Identification of Cereblon E3 Ubiquitin Ligase Ligands and Their Application in HDAC6 Degraders.
    Yang K; Zhao Y; Nie X; Wu H; Wang B; Almodovar-Rivera CM; Xie H; Tang W
    Cell Chem Biol; 2020 Jul; 27(7):866-876.e8. PubMed ID: 32413286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bivalent Ligands for Protein Degradation in Drug Discovery.
    Scheepstra M; Hekking KFW; van Hijfte L; Folmer RHA
    Comput Struct Biotechnol J; 2019; 17():160-176. PubMed ID: 30788082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PROTAC-induced Protein Functional Dynamics in Targeted Protein Degradation.
    Wu KY; Hung TI; Chang CA
    bioRxiv; 2024 May; ():. PubMed ID: 38746111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PROTACs: Current Trends in Protein Degradation by Proteolysis-Targeting Chimeras.
    Madan J; Ahuja VK; Dua K; Samajdar S; Ramchandra M; Giri S
    BioDrugs; 2022 Sep; 36(5):609-623. PubMed ID: 36098871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One-Pot Synthesis of Cereblon Proteolysis Targeting Chimeras via Photoinduced C(sp
    Arndt CM; Bitai J; Brunner J; Opatz T; Martinelli P; Gollner A; Sokol KR; Krumb M
    J Med Chem; 2023 Dec; 66(24):16939-16952. PubMed ID: 38096359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders.
    Diehl CJ; Ciulli A
    Chem Soc Rev; 2022 Oct; 51(19):8216-8257. PubMed ID: 35983982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. E3 ligase ligand chemistries: from building blocks to protein degraders.
    Sosič I; Bricelj A; Steinebach C
    Chem Soc Rev; 2022 May; 51(9):3487-3534. PubMed ID: 35393989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.